Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × MEK inhibitor I × Dermatologic × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Nivolumab 8 pembrolizumab 6 Ipilimumab 5 Niacinamide 3 Magnetic Resonance Spectroscopy 3 Itraconazole 3 Biopsy 3 resiquimod 2 encorafenib 2 durvalumab 2 calcipotriene 2 binimetinib 2 Radiotherapy 2 Niacin 2 MART-1 Antigen 2 Imiquimod 2 Fluorouracil 2 Ascorbic Acid 2 tremelimumab 1 tetraethylpyrazine 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 relatlimab 1 montanide ISA 51 1 glucopyranosyl lipid-A 1 clevudine 1 cemiplimab 1 avelumab 1 arsenous acid 1 X-Rays 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382549 2023-12-12

Mel61

University of Virginia

Phase EARLY_PHASE1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡